FDA proposes guidance for nonclinical safety assessment of oligonucleotide-based drugs
Regulatory NewsFerdous Al-Faruque
Biologics/ biosimilars/ vaccinesGuidancePharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)